Kadimastem (XTAE:KDST) NonCurrent Deferred Liabilities: ₪0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:KDST Kadimastem Ltd XTAE:KDST
21 GF Score
Price ₪39.58
! 4 Warning Signs
View Full Analysis

What is Kadimastem NonCurrent Deferred Liabilities?

Kadimastem XTAE:KDST 21 NonCurrent Deferred Liabilities is ₪0.00 Mil as of Dec. 2025. GuruFocus rates XTAE:KDST with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Kadimastem's non-current deferred liabilities for the quarter that ended in Dec. 2025 was ₪0.00 Mil.

Kadimastem NonCurrent Deferred Liabilities Related Terms

Kadimastem NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Kadimastem's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kadimastem NonCurrent Deferred Liabilities Chart

Kadimastem Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kadimastem Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XTAE:KDST
21GF Score
Kadimastem Ltd XTAE:KDST
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of ₪0.00 Mil mean?
Kadimastem (XTAE:KDST) has a NonCurrent Deferred Liabilities of ₪0.00 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Kadimastem and its competitors.
Is Kadimastem's NonCurrent Deferred Liabilities too high?
Kadimastem's current NonCurrent Deferred Liabilities is ₪0.00 Mil. Overall, Kadimastem has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Kadimastem's NonCurrent Deferred Liabilities compare to MRKR and HOWL?
Kadimastem's NonCurrent Deferred Liabilities of ₪0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Kadimastem and its competitors. Kadimastem's current NonCurrent Deferred Liabilities is ₪0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kadimastem stock overvalued right now?
Kadimastem (XTAE:KDST) has a current NonCurrent Deferred Liabilities of ₪0.00 Mil. The current NonCurrent Deferred Liabilities is ₪0.00 Mil. Kadimastem's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Kadimastem (XTAE:KDST), the current NonCurrent Deferred Liabilities is ₪0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kadimastem Business Description

Other Exchanges NCEL:USA
Address Hohstrasse 1, Kloten, CHE, 8302
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
21GF Score

Get the complete analysis for XTAE:KDST

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪39.58
Price